Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (26)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tan, S. V.
Right arrow Articles by Scaravilli, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tan, S. V.
Right arrow Articles by Scaravilli, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 118, No. 5, 1247-1261, 1995
© 1995 Guarantors of Brain

research-article

AIDS-associated vacuolar myelopathy A morphometric study

S. V. Tan1,2, R. J. Guiloff1 and F. Scaravilli2

1Regional Neurosciences Centre, Charing Cross Hospital London, UK 2Department of Neuropathology, Institute of Neurology London, UK

Correspondence to: Professor F. Scaravilli, Department of Neuropathology, Institute of Neurology, Queen Square, London WCIN 3BG, UK

The post-mortem pathology in 20 spinal cords of human immunodeficiency virus (HIV) infected patients with vacuolar myelopathy was quantified by evaluating (i) the intensity of myelin change, vacuolation and macrophage density; and (ii) the areas of white matter covered by each feature. Severity scores were constructed for (i) the anterior, lateral, and posterior white matter columns; (ii) each level of spinal cord; and (iii) the whole spinal cord [Cord Total and Cord Average Severity Scores (CTSS, CASS)]. Astroglial activation was scored separately. In 14 cords with mild-moderate vacuolar myelopathy (CASS = 23–259), macrophages were the most prominent pathological feature, and level severity scores were higher at mid-thoracic than cervical levels (P = 0.009). In six cords with severe vacuolar myelopathy (CASS = 396–614), vacuolation, demyelination and macrophages were equally evident and thoracic and cervical level severity scores were similar. The most severe lesions showed evidence of clearing of macrophages from the collapsed centres. A clinical lower limb score correlated with the anterior (P = 0.03) and lateral (P = 0.04) column total scores and with the CTSS (P = 0.04) in the nine patients who had had both myelopathy related disability and all cord levels available. There was no significant longitudinal gradient in score severity in the posterior, lateral or anterior columns and no evidence of a dying-back phenomenon. There was no evidence of Wallerian degeneration occurring as a primary process. Astroglial activation did not correlate with the severity or duration of the vacuolar myelopathy. Detection of HIV p24 antigen in the spinal cord related to the local presence of multinucleated giant cells and to antigen expression in the brain but not with the severity of vacuolar myelopathy. The pathology in vacuolar myelopathy appeared to start in the mid-low thoracic cord, with increasing rostral involvement as the disease became more severe. The relative prominence of macrophages in mild-moderate lesions suggests they may be involved early in the pathogenesis of vacuolar myelopathy.

vacuolar myelopathy; HIV-1; AIDS; morphometry; macrophages

Received December 29, 1995. Revised March 22, 1995. Accepted May 30, 1995.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
S R L Stacpoole, R Phadke, T S Jacques, T Revesz, and G T Plant
Vacuolar myelopathy associated with optic neuropathy in an HIV-negative, immunosuppressed liver transplant recipient
J. Neurol. Neurosurg. Psychiatry, May 1, 2009; 80(5): 581 - 583.
[Full Text] [PDF]

Home page
 NeurologyHome page
A. Di Rocco, P. Werner, T. Bottiglieri, J. Godbold, M. Liu, M. Tagliati, A. Scarano, and D. Simpson
Treatment of AIDS-associated myelopathy with L-methionine: A placebo-controlled study
Neurology, October 12, 2004; 63(7): 1270 - 1275.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. Di Rocco, T. Bottiglieri, P. Werner, A. Geraci, D. Simpson, J. Godbold, and S. Morgello
Abnormal cobalamin-dependent transmethylation in AIDS-associated myelopathy
Neurology, March 12, 2002; 58(5): 730 - 735.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. Rottnek, A. Di Rocco, D. Laudier, and S. Morgello
Axonal damage is a late component of vacuolar myelopathy
Neurology, February 12, 2002; 58(3): 479 - 481.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. Martin, G. Solders, A. Sonnerborg, and P. Hansson
Antiretroviral therapy may improve sensory function in HIV-infected patients: A pilot study
Neurology, June 13, 2000; 54(11): 2120 - 2127.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
J. Chong, A. D. Rocco, M. Tagliati, F. Danisi, D. M. Simpson, and S. W. Atlas
MR Findings in AIDS-Associated Myelopathy
AJNR Am. J. Neuroradiol., September 1, 1999; 20(8): 1412 - 1416.
[Abstract] [Full Text]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
S V Tan and R J Guiloff
Hypothesis on the pathogenesis of vacuolar myelopathy, dementia, and peripheral neuropathy in AIDS
J. Neurol. Neurosurg. Psychiatry, July 1, 1998; 65(1): 23 - 28.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.